Recent Updates
Recently added Catalysts
RGNX Positive Sentiment Score: 68/100

REGENXBIO to Participate in Upcoming Investor Conferences

Tuesday, May 6, 2025 2 min read
Key Takeaway: REGENXBIO Inc. announced its participation in several upcoming investor conferences, including the BofA Securities Health Care Conference and the RBC Global Healthcare Conference. These conferences will feature various presentations and fireside chats to engage potential investors. The participation underscores REGENXBIO's ongoing efforts to highlight its advancements in gene therapy, particularly its late-stage pipeline targeting rare diseases. Live webcasts of the events will be available through the company’s website, providing additional insights to stakeholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • REGENXBIO will participate in multiple high-profile investor conferences.
  • The company showcases a commitment to engage with investors and stakeholders.
  • The participation indicates potential interest and growth in their gene therapy pipeline.

Full Press Release Details

ROCKVILLE, Md., May 6, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:
BofA Securities Health Care Conference 2025
Presentation: Tuesday, May 13, 2025 at 5:00 p.m. PT
Location: Las Vegas, NV
RBC Global Healthcare Conference
Fireside Chat: Tuesday, May 20, 2025 at 11:30 a.m. ET
Location: New York, NY
H.C. Wainwright BioConnect
Fireside Chat: Tuesday, May 20, 2025 at 4:00 p.m. ET
Location: New York, NY
Stifel Virtual Ophthalmology Forum
Fireside Chat: Tuesday, May 27, 2025 at 9:30 a.m. ET
UBS Spring Biotech Conference
1x1 Investor Meetings: Tuesday, June 24, 2025
Location: New York, NY
Live webcasts of select presentations and fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Corporate Communications
George E. MacDougall
SOURCE REGENXBIO Inc.

21 %

more press release views with

Frequently Asked Questions

What are REGENXBIO's upcoming investor conferences?

REGENXBIO will participate in several conferences, including BofA, RBC, and Stifel, among others.

When will REGENXBIO present at the BofA conference?

REGENXBIO will present at the BofA Securities Health Care Conference on May 13, 2025.

Where can I access live webcast of REGENXBIO's presentations?

Live webcasts can be accessed in the Investors section of REGENXBIO's website.

What is REGENXBIO known for?

REGENXBIO is recognized for pioneering AAV gene therapy for treating rare diseases.

What types of diseases does REGENXBIO's pipeline target?

The pipeline targets rare and retinal diseases, including Duchenne and MPS disorders.

Tags: RGNX Viatris Investor Conferences Healthcare REGENXBIO gene therapy investor conferences biotech
Last updated: May 6, 2025